CRH (CRH) H2 2017 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2017 earnings summary
19 Nov, 2026Executive summary
Generated €3.3bn EBITDA; organic EBITDA growth was 3% amid severe weather disruption, with margins and returns improving for a fourth consecutive year.
Portfolio activity was significant: nearly €5bn spent on acquisitions, alongside the sale of Allied; operating cash generation reached €2.2bn.
Financial highlights
Organic EBITDA growth was 3%; Americas and Europe each delivered 5% organic growth, while Asia’s decline reduced the group result.
Cash from operations was €2.2bn, representing 70% EBITDA-to-cash conversion; working capital as a percentage of sales remained at the prior-year level.
Proposed dividend of €0.68 per share, up 5% YoY; dividend cover was 2.4x excluding the Swiss pension gain and deferred-tax benefit.
Outlook and guidance
2018 expected to deliver another year of growth, with improved performance in key metrics; early-year U.S. activity and backlogs appeared robust.
European recovery and pricing momentum were expected to continue; heavy-side price increases were anticipated across more countries, though the year was too early for quantified guidance.
Philippines performance may not improve at the bottom line in 2018; stabilization and recovery were expected from 2019.
Group CapEx was expected near 104% of depreciation before Philippines expansion spending; the expansion’s first phase was budgeted at €120m–€125m over 12–18 months.
U.S. aggregates pricing was expected in a 3%–5% range in 2018, depending on region; asphalt margins were expected to expand.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026